Johnson & Johnson (NYSE:JNJ) Shares Sold by Clear Street Markets LLC

Clear Street Markets LLC reduced its position in Johnson & Johnson (NYSE:JNJGet Rating) by 37.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,315 shares of the company’s stock after selling 4,370 shares during the period. Clear Street Markets LLC’s holdings in Johnson & Johnson were worth $1,195,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Morton Brown Family Wealth LLC raised its holdings in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $39,000. First Bank & Trust lifted its position in shares of Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares during the last quarter. Heritage Wealth Management LLC bought a new stake in Johnson & Johnson in the second quarter valued at about $84,000. Finally, Timber Creek Capital Management LLC raised its stake in Johnson & Johnson by 225.0% during the third quarter. Timber Creek Capital Management LLC now owns 650 shares of the company’s stock valued at $106,000 after buying an additional 450 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. StockNews.com started coverage on Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Credit Suisse Group began coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target on the stock. Sanford C. Bernstein dropped their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Citigroup upped their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Finally, SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $181.75.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the sale, the executive vice president now owns 41,813 shares in the company, valued at approximately $7,336,927.11. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the sale, the executive vice president now owns 41,813 shares in the company, valued at approximately $7,336,927.11. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Over the last three months, insiders have sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.31 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The firm’s 50-day simple moving average is $175.98 and its 200 day simple moving average is $171.06. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a market cap of $440.04 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.23 by $0.12. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. During the same period in the previous year, the business earned $2.13 earnings per share. Johnson & Johnson’s revenue for the quarter was down 4.4% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.